Evidence map›Paper›PMID 42429032›Full record

ArticleCell proliferation2026

Optimising Haematopoietic Stem Cell Transplantation: Enhancing Myeloablation Sensitivity and Alleviating Anaemia Using Roxadustat (FG-4592).

Guanheng Yang, Jiahui Wu, Xinbing Guo, Wenchen Shen, Xiao Sang, Xiuli Gong, Shu-Zhen Huang, Jingzhi Zhang, Fanyi Zeng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell proliferation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guanheng YangShanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiahui WuShanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xinbing GuoShanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wenchen ShenShanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiao SangShanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiuli GongShanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shu-Zhen HuangShanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jingzhi ZhangShanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Fanyi ZengShanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

Innovative Research Team of High-Level Local University in Shanghai SHSMU-ZDCX20212200Macau Science and Technology Development Fund (FDCT) 003/2022/ALCMacau Science and Technology Development Fund (FDCT) 0092/2022/A2National Key Research and Development Program of China 2019YFA0801402National Key Research and Development Program of China 2024YFC2707002National Natural Science Foundation of China 32570951National Natural Science Foundation of China 82271890National Natural Science Foundation of China U23A20498
6 · The paper itself

Abstract

Haematopoietic stem cell transplantation (HSCT) is an effective therapy for a broad range of hematologic, autoimmune and genetic diseases. Successful HSCT requires adequate myeloablation to create space in the bone marrow microenvironment for donor haematopoietic stem and progenitor cells. Standard conditioning with busulfan and cyclophosphamide (BuCy), although widely used, may not completely clear recipient cells and can cause significant toxicity. Roxadustat (FG-4592), a hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat renal anaemia, modulates HIF-1α stability and influences erythropoiesis, iron metabolism and cellular stress responses. Here, we investigated whether co-administration of FG-4592 during BuCy conditioning improves myeloablation efficiency and enhances donor-cell engraftment. Our results show that FG-4592 increases the sensitivity of bone marrow mononuclear cell (BM-MNC) populations to BuCy conditioning, promoting deeper depletion of both haematopoietic and non-haematopoietic recipient cells. This improved clearance supports enhanced donor-cell residency following transplantation. Furthermore, in β

Indexed as

bone marrow microenvironmenthaematopoietic stem cellmyeloablationRoxadustat (FG‐4592)thalassaemiatransplantation

Identifiers

PMID42429032
PMCPMC13352331

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.